Outlook Therapeutics, Inc. - Common Stock (OTLK)

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Outlook Therapeutics shares fall after the FDA rejects its ONS-5010 wet AMD drug application, citing insufficient efficacy evidence despite prior trial success.

The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Let's have a look at the gap up and gap down stocks in today's session.

As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Outlook Therapeutics plans to resubmit ONS-5010 for FDA approval in 2025 following NORSE EIGHT trial results in wet AMD patients.